Stay up to date with the latest Mycovia news, press releases, and more. If you have any questions or comments regarding media inquiries, please reach out to mediarelations@mycovia.com.

10.21.2020

Mycovia Pharmaceuticals, Inc. Announces Last Patient Completes Final Visit in their Global Phase 3 “VIOLET Studies” for Oteseconazole (VT-1161) for the treatment of recurrent vulvovaginal candidiasis (RVVC)

Download PDF

08.26.2020

Mycovia Pharmaceuticals Announces Peer-Reviewed Publication of Positive Study Results of Oteseconazole for the Treatment of Acute Vulvovaginal Candidiasis

Download PDF

08.06.2020

Mycovia Pharmaceuticals CEO Patrick Jordan Named 2020 Life Sciences CEO of the Year by Triangle Business Journal

Download PDF

06.08.2020

Mycovia Pharmaceuticals to Participate in On-Demand Women’s Health Panel at BIO Digital 2020

Download PDF

02.11.2020

Mycovia Pharmaceuticals Initiates Extension Clinical Studies to Further Evaluate Long-Term Efficacy of Oteseconazole (VT-1161) in Patients with Recurrent Vulvovaginal Candidiasis

Download PDF
Transforming healthcare together Careers at Mycovia
Working together to transform healthcare Contact Us